Interstitial lung abnormalities: new insights between theory and clinical practice

Roberta Eufrasia Ledda¹, Gianluca Milanese¹*, Francesca Milone¹, Ludovica Leo², Maurizio Balbi¹, Mario Silva¹ and Nicola Sverzellati¹

Abstract
Interstitial lung abnormalities (ILAs) represent radiologic abnormalities incidentally detected on chest computed tomography (CT) examination, potentially related to interstitial lung diseases (ILD). Numerous studies have demonstrated that ILAs are associated with increased risk of progression toward pulmonary fibrosis and mortality. Some radiological patterns have been proven to have a higher risk of progression. In this setting, the role of radiologists in reporting these interstitial abnormalities is critical. This review aims to discuss the most recent advancements in understanding this radiological entity and the open issues that still prevent the translation from theory to practice, emphasizing the importance of ILA recognition and adequately reporting in clinical practice.

Keywords: Interstitial lung abnormalities, Interstitial lung disease, Multidetector computed tomography, Terminology, Multidisciplinary approach

Keypoints
- Interstitial lung abnormality (ILA), perceived as a niche topic, is underreported in clinical practice.
- Adequate terminology is key for the adequate management of ILA.
- The role of radiologist goes beyond the mere recognition of ILA.

Background
The use of chest high-resolution computed tomography (HRCT) in clinical practice and its continuous implementation have revolutionized the diagnosis of interstitial lung diseases (ILDs), contributing to an increasing interest in such topic by both radiologists and clinicians [1–3]. The interpretation of chest HRCT, however, is a complex process [2, 4] and the recognition of mild interstitial abnormalities might be rather challenging. In fact, the relative ease of assessing severe and extensively distributed abnormalities strongly contrasts with the difficulty of depicting subtle and less extensive ILD, at risk of being overlooked. Subclinical high density interstitial abnormalities can be displayed in patients undergoing either partial or complete chest CT examination, without clinical suspicion of underlying ILD. These incidentally detected CT findings, potentially representing symptomatic ILD, are now called interstitial lung abnormalities (ILAs) [5].

The reported association between ILA and adverse outcomes (e.g., all-cause mortality, hospitalization, progressive functional decline, increased lung cancer risk, etc.), as well as the blurred burden between ILAs and idiopathic pulmonary fibrosis (IPF) in some individuals, strongly suggest a potential clinical significance of ILAs. Although the progression of ILA toward pulmonary fibrosis has been proven in some patients’ cohorts [6], not all cases of ILA represent or evolve toward overt ILD [7]. Current diagnostic strategies are focused onto the separation between clinically irrelevant ILA and clinically
significant ILA, which might benefit from early treatment with antifibrotic therapies [5].

To date, the estimated prevalence of ILA in subjects older than 60 years of age is up to 9% in smokers and 7% in non-smokers [8], reaching the rate of 9.7% [9] and 25% [10] in lung cancer screening cohorts. Radiologists represent the frontline of ILA detection and characterization, somewhat of a gatekeeper in the gaze between early detection and/or overdiagnosis/overinvestigation. Because ILA is usually incidental, this (pre)clinical matter is extended beyond the cohort of chest radiologists. ILA, however, seems to be underappreciated by radiologists despite the incremental number of CT referrals for diagnostic purposes as well as the implementation of lung cancer screening programs [10–13].

Since ILAs were first described in tobacco smokers [14–16], numerous studies have attempted to characterize these CT abnormalities [6, 12, 17], leaving unanswered questions. Aiming at addressing some of these questions, the Fleischer Society has recently released a Position Paper that provides clarity to the definition, terminology, risk factors and management of ILA [5]. This review article discusses the new insight into this subclinical entity and the open issues that still prevent ILA to be appropriately managed. Future perspectives on a multidisciplinary approach of ILA and the potential role of quantitative imaging in such setting are also discussed.

What’s new?

Prior to the Fleischner Society’s Position Paper, an heterogeneous terminology had been used to describe ILA, including (1) ILD at an early stage, (2) early ILD, (3) preclinical ILD and (4) subclinical ILD [5, 18, 19], all suggesting a relentless progression toward ILD. Such heterogeneity along with the lack of a standardized terminology has likely contributed to ILA been erroneously perceived as a niche topic, prerogative of either respiratory physicians or chest radiologists. The Fleischner Society’s Position Paper attempts to fill this gap, emphasizing the importance of ILA being appropriately recognized and reported by radiologists in their routine practice.

ILAAs are defined as non-dependent lung abnormalities [20], diffuse in distribution (i.e., non-focal) and with at least 5% extent of a lung zone (upper, middle, and lower lung zones are demarcated by the levels of the inferior aortic arch and right inferior pulmonary vein), depicted in individuals in whom ILD is not suspected and thus, incidentally [5]. CT findings accounting for ILA include ground-glass or reticular opacities, honeycombing, and non-emphysematous cysts. Once such abnormalities have been recognized, radiologists are to report which lung regions are involved as different distribution patterns may have different prognostic implications [21]. In particular, Hatabu et al. proposed three CT categories of ILAs: (1) non-subpleural ILAs (Fig. 1), (2) subpleural non-fibrotic ILAs (Figs. 2, 3) and (3) subpleural fibrotic ILAs (Figs. 4, 5, 6), where CT features of lung fibrosis include architectural distortion (e.g., fissures displacement, bronchovascular structures distortion) with traction bronchiectasis, and/or honeycombing (or both) [5]. These categories were shown to be associated with different risk of progression and mortality [7, 9]. For instance, non-subpleural ILAs tend to remain stable and do not correlate with increased mortality, while the opposite is true for subpleural fibrotic ILAs [7, 9]. The distinction between fibrotic and non-fibrotic ILA is paramount yet challenging in limited or early disease (e.g., mild subpleural reticular opacities) because CT histologic correlation in this setting is imperfect. In one patient, limited subpleural reticulation may be the sole CT manifestation of histologically advanced fibrosis but in another may not represent fibrosis at all [22].

The exclusion of the centrilobular nodules from the list of ILAs features represents a meaningful change from prior definitions and remarks the importance of focusing on those CT abnormalities that are more at risk of progression [9]. Other CT findings that have been removed from the list of interstitial abnormalities potentially regarded as ILAs include focal and unilateral ground glass opacities (GGO) since they are unlikely to represent ILD (typically bilateral), patchy GGO and tree in bud nodularity, especially if involving the lower lobes as more likely related to aspiration [23].

Fig. 1 Axial CT image without contrast (slice thickness of 1.5 mm) of a 64-year-old lady shows bilateral GGOs in the lower lobes and fine reticular opacities (white circle) with subpleural sparing, compatible with non-subpleural ILAs.
Although the management of subjects with ILAs should be driven by both CT and clinical features, even fully asymptomatic individuals with ILAs can be subcategorized at risk of progression or not at risk of progression merely according to the CT pattern, here the pivotal role of radiologist in skilled triggering of work-up. Notably, subpleural fibrotic ILAs are deemed to be more at risk to progress toward frank pulmonary fibrosis. Putman et al. observed that evidence of subpleural reticular abnormalities, lower lobe changes and traction bronchiectasis were associated with a sixfold increase odds of radiological progression. They also reported that all cases displaying honeycombing had progressed over the following 5 years [7].

ILA is incidentally detected, but respiratory symptoms may be present, in which case such interstitial abnormalities likely represent ILD and are only temporarily labeled as ILAs. A set of clinical questions are suggested to rule out any respiratory symptoms that would require referral to pulmonologist otherwise. Critical clinical information includes history of cigarette smoking, other inhalational exposures, medications, radiation therapy and thoracic surgery [24].

The Fleischner Society’s Position Paper also emphasizes the importance of reporting the ILAs in cancer patients. The combination of cancer and ILA increases the risk of developing severe pneumonitis as a side effect of immunotherapy (immune checkpoint inhibitors), systemic chemotherapy and radiation therapy [25–29].
Furthermore, these subjects are more likely to suffer from surgery complications, including acute respiratory distress syndrome (ARDS) [30], suggesting that ILA might have clinical implication that goes beyond the risk of progression toward pulmonary fibrosis, and thus, reinforcing the importance of not to disregard such interstitial abnormalities.

**Open issues**

Despite the remarkable contribution provided by Fleischner Society’s Position Paper [5], several questions still need to be addressed, some of which are related to limitations that might be appreciated in clinical practice at the time of both ILA first identification and subsequent evaluations.

**Identification of ILA**

ILAs can be found on either abdominal or chest CT performed for any indication (Figs. 5, 6). This would trigger a chest CT to confirm and better characterize the CT abnormalities that were incidentally detected. However, in whom and when a dedicated CT should be performed is still an open question that warrants clearer recommendations. Furthermore, it might be questioned whether referring asymptomatic subjects for an additional CT...
scan is appropriate, particularly younger individuals because of the risks related to radiation exposure. The use of a low-dose chest CT protocol is accepted for evaluating fibrotic lung disease [31]. Nonetheless, more data are needed to understand the technical CT requirements for scanning subjects with suspected ILAs.

A chest CT scan optimized for the detection of interstitial abnormalities can be of value in symptomatic patients to provide detailed information on both findings and distribution, since different patterns of ILAs have been proved to have different implications in terms of risk of progression toward pulmonary fibrosis [7, 9]. Identifying symptomatic subjects who might benefit from an additional scan, however, can be challenging in a busy radiological department. Incidental findings, including ILAs, are usually depicted at the time of reporting, when patients are unavailable to be questioned. Moreover, investigating the presence of symptoms unrelated to the clinical indication for which the patient is referred, is rather difficult. In this scenario, standardized reporting is expected to sync radiological impression and the subsequent clinical management by referring physician, when appropriate. A pragmatic approach is offered by the National Health Service (NHS) of England in their document for targeted screening of lung cancer by low-dose CT [32], but dedicated analyses are still eagerly awaited. In case of mild ILD, symptoms can be subtle, and their identification might require a set of detailed questions. Furthermore, recognizing subjects at high risk of progression among those with no symptoms appears not less challenging, since investigating the presence of both clinical and demographic risk factors can be likewise problematic.

It must be acknowledged that most data on ILAs were obtained from studies involving research participants from general population cohorts, and from populations of smokers enriched for the presence of chronic-obstructive pulmonary disease (COPD), cardiovascular and lung cancer screening cohorts [9, 11, 12, 24, 33–37]. Indeed, those cohorts mostly included either elderly [9, 38, 39] or smokers [14, 34], thus subjects at greater risk of ILAs. Although incidental findings have also being increasingly recognized in every type of CT scan, further data are needed to figure out the prevalence of the ILAs in daily practice.

**Progression of ILA**

Disease progression at CT is of both diagnostic and prognostic value. However, definition of disease progression deserves further clarification. In fact, ILAs as well
as any ILD may change in both extent and morphology over time. However, it is not clear how disease progression should be assessed. ILAs are often mild in extent and a marginal longitudinal increase may be difficult to appreciate. Therefore, an accurate anatomical matching of the CT images obtained at different timepoints is at least required to evaluate the longitudinal behavior of the ILAs. Furthermore, it is not clear if and to what extent the development of new findings (e.g., new traction bronchiolectasis, more reticular opacities, etc.) should be regarded as established signs of disease progression.

Whether a mere radiological progression should be managed as a progressed ILA regardless of the presence of respiratory symptoms is still to be defined. Araki et al. demonstrated a correlation between radiological and functional progression, observing that patients with evidence of radiological progression showed an accelerated decline in pulmonary function [6]. However, evidence of radiological progression might not necessarily be associated with a worsening of pulmonary function and/or symptom occurrence [40]. Should these cases be regarded as progressed? Targeting high-risk patients is crucial from a therapeutic perspective, since the use of antifibrotic drugs, already employed in IPF [31, 41], has been proposed in ILA patients at high risk of progression. The definition of specific risk factors for progression will also allow to follow-up these subjects appropriately. Up to now, the correct clinical and radiological follow-up timing is still unknown. A clinical 3–12 months follow-up along with a repeat CT scan at 12–24 months is deemed acceptable for ILA patients at high risk of progression (Fig. 7), in whom a further follow-up after the first year can be considered [5]. Follow-up frequency and duration after the first year has not yet been defined and the optimal method for assessment of progression of such minor findings is still to be analyzed, as previously done in clinically apparent ILDs [42, 43].

Interestingly, Copley et al. observed ILAs in normal subjects over the age of 75 years and not in subjects with less than 55 years of age [44]. They also reported that the majority of these abnormalities were not associated with respiratory symptoms nor with declined pulmonary function and therefore, not in need of follow-up or treatment. However, the borderlands of the normal for the ILAs are still not defined [45].

**Future perspectives**

As discussed above, mild interstitial abnormalities might have already been causing symptoms and some are at high risk of progression [46]. A correct management demands a thorough patient assessment, which should spark from skilled radiological characterization. However, any general or subspecialty radiologist might encounter these findings and is expected to play a role in their management, mostly guided by the risk of progression and thus, by the CT pattern, either fibrotic or non-fibrotic, whose definition is entirely on radiologist. Nonetheless, beside the characterization of the CT pattern, radiologist can provide practical recommendations, suggesting a radiological follow-up for fibrotic ILA or a pulmonary evaluation for symptomatic subjects. In this context, a multidisciplinary approach to this radiological entity seems to be the optimal management and thus, should be encouraged. The risk stratification by a comprehensive evaluation of predisposing factors might be of great value for focusing on appropriate elevation of ILA.

---

**Fig. 7** Flowchart summarizing the suggested management of ILA. Adapted from Reference [5]
into the clinical domain, eventually helped by investigation of symptoms. This approach might be easier and more relevant in patients with other comorbidities (e.g., COPD). Noteworthy, patients with history of ILA and COPD are at a higher risk of pulmonary fibrosis and COPD exacerbations [33].

Establishing the extent of ILAs by a purely visual assessment may not be an easy task for radiologists, even for chest radiologists among whom there is a high interobserver variability. The identification of ILA and its pattern recognition is indeed subjective to reader expertise and substantially affected by interobserver variability, even among experts [22, 47–49]. Notably, Walsh et al. demonstrated that even in case of overt lung fibrosis, the interobserver agreement among thoracic radiologists of varying levels of experience is at best only moderate [50]. The 5% threshold embraced by the Position Paper to define the presence of ILA seems quite prone to subjective interpretation, while the accurate quantification of the abnormal parenchyma is of utmost importance at the time of both diagnosis and follow-up. Signs of frank progression can be easily detected as compared to subtle changes, which are more likely to be overlooked. However, subtle progression of minor findings might still represent a substantial relative increase in extent (progression from 6 to 8% extent represents a relative increase in one third).

Quantitative imaging techniques, successfully used to score the proportion of parenchymal involvement in diffuse lung diseases [51–55], ensure objectiveness and reproducibility and might be efficiently employed also in ILA. However, significant discrepancies between visual and automated assessment in ILD have been described and future studies will be needed to overcome this limitation. Jacob et al., for instance, observed how fine reticular abnormalities overlaying on GGOs were scored as merely GGOs by the quantitative software [42]. Of note, when fibrotic changes (more often involving the lower lobes) progress, the healthy lung regions (usually the upper lobes) might hyper-expand, as a result of a compensatory response [56]. These changes can be misinterpreted by the quantitative software, for which an increased extent of fibrosis in absolute terms may be scored as a relatively smaller volume of fibrotic lung and thus, underestimated [42]. Recent advances in the field of artificial intelligence and machine learning seem to offer great opportunities in medical imaging [57, 58]. A detailed discussion of the numerous potential applications of machine learning in diagnostic imaging goes beyond the aim of this review. Among others, such applications include the possibility for integrating radiological and clinical data, which will help in redefining the real risk of progression at the time of diagnosis and establishing the severity of progression.

Conclusion

Despite the remarkable advances in understanding this radiological entity, several issues are still debated. Undoubtedly, the Position Paper recently released by the Fleischner Society has addressed some of the open questions, giving a major contribution on definition and terminology, easing the important task of reporting these often subtle interstitial abnormalities. Future studies on general population, however, are fostered to investigate ILAs risk factors, whereas a multidisciplinary approach seems to be the right answer to the optimal management.

Abbreviations

ARDS: Acute respiratory distress syndrome; COPD: Chronic obstructive pulmonary disease; CT: Computed tomography; GGO: Ground glass opacity; HRCT: High resolution computed tomography; ILAs: Interstitial lung abnormalities; ILD: Interstitial lung disease; IPPF: Idiopathic pulmonary fibrosis; NHS: National Health Service.

Authors’ contributions

(I) Conception and design: REL, NS; (II) Provision of study materials: FM, LL, MB; (III) Manuscript writing: REL, GM, MS, NS. (IV) All authors read and approved the final manuscript.

Funding

None.

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1 Unit of “Scienze Radiologiche” (Pad. Barbieri), Department of Medicine and Surgery (DiMeC), University Hospital of Parma, via Gramsci 14, 43126 Parma, Italy. 2 Department of Medicine and Surgery (DiMeC), University of Parma, Parma, Italy.

Received: 7 September 2021 Accepted: 8 December 2021
Published online: 15 January 2022

References

1. Walsh SL, Hansell DM (2014) High-resolution CT of interstitial lung disease: a continuous evolution. Semin Respir Crit Care Med 35(1):129–144
2. Nishino M, Itoh H, Hatabu H (2014) A practical approach to high-resolution CT of diffuse lung disease. Eur J Radiol 83(1):6–19
3. Kokosi MA, Margaritopoulos GA, Wells AU (2018) Personalised medicine in interstitial lung diseases: Number 6 in the Series “Personalised medicine in respiratory diseases” Edited by Renaud Louis and Nicolas Roche. Eur Respir Rev 27(148):170117
4. Gruden JF, Naidich DP, Machnicki SC, Cohen SL, Girvin F, Raio C, S (2020) An algorithmic approach to the interpretation of diffuse lung disease on chest CT imaging: a theory of almost everything. Chest 157(3):612–635
5. Hatabu H, Hunninghake GM, Richeldi L et al (2020) Interstitial lung abnormalities detected incidentally on CT: a position paper from the Fleischner Society. Lancet Respir Med 8(7):726–737
6. Araki T, Putman RK, Hatabu H et al (2016) Development and progression of interstitial lung abnormalities in the Framingham Heart Study. Am J Respir Crit Care Med 194(12):1514–1522
7. Putman RK, Gudmundsson G, Axelsson GT et al (2019) Imaging patterns are associated with interstitial lung abnormality progression and mortality. Am J Respir Crit Care Med 200(2):175–183
8. Hatabu H, Hunninghake GM, Lynch DA (2019) Interstitial lung abnormality: recognition and perspectives. Radiology 291(1):1–3
9. Jin GY, Lynch D, Chavala A et al (2013) Interstitial lung abnormalities in a CT lung cancer screening population: prevalence and progression rate. Radiology 268(2):563–571
10. Chung JH, Richards JC, Koelch TL, MacMahon H, Lynch DA (2018) Screening for lung cancer: incidental pulmonary parenchymal findings. AJR Am J Roentgenol 210(3):503–513
11. Sverzellati N, Guerci L, Randi G et al (2011) Interstitial lung disease in a low-dose computed tomography screening population. Am J Radiol 200(2):175–183
12. Sverzellati N, Randi G, Spagnolo P et al (2013) Increased mean lung density: another independent predictor of lung cancer? Eur J Radiol 82(8):1325–1331
13. Hunninghake GM, Hatabu H, Okajima Y et al (2013) MUC5B promoter polymorphism and interstitial lung abnormalities. N Engl J Med 368(23):2192–2200
14. Kashiwabara K (2006) Characteristics and disease activity of early interstitial lung disease in subjects with true parenchymal abnormalities in the posterior subpleural aspect of the lung. Chest 129(2):402–406
15. Gochoico BR, Avila NA, Chow CK et al (2008) Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med 168(2):159–166
16. Hansell DM, Bankier AA, MacMahon H, McLeod TC, Muller NL, Remy J (2008) Fleischner Society: glossary of terms for thoracic imaging. Radiology 246(3):697–722
17. Salisburis ML, Hewlett JC, Ding G et al (2020) Development and progression of radiologic abnormalities in individuals at risk for familial interstitial lung disease. Am J Respir Crit Care Med 201(10):1230–1239
18. Washko GR, Hunninghake GM, Fernandez IE et al (2011) Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med 364(10):897–906
19. Lederer DJ, Enright PL, Kawut SM et al (2009) Cigarette smoking is associated with subclinical parenchymal lung disease: the Multi-Ethnic Study of Atherosclerosis (MESA)-lung study. Am J Respir Crit Care Med 180(5):407–414
20. Sverzellati N, Randi G, Spagnolo P et al (2013) Increased mean lung density: another independent predictor of lung cancer? Eur J Radiol 82(8):1325–1331
21. Hickey B, Aihara K, Enright P et al (2018) Use of thin-section CT in the diagnosis of idiopathic pulmonary fibrosis: a multicentre study. Thorax 73(1):23–30
22. Hatabu H, Hunninghake GM, Richeldi L et al (2020) Interstitial lung abnormalities. Eur J Radiol 2019:1–3
23. Nakanishi Y, Masuda T, Yamaguchi K et al (2019) Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer. Respir Investig 57(5):451–459
24. Hisao H, Kubo T, Makimoto S et al (2019) Chemoradiotherapy for locally advanced lung cancer patients with interstitial lung abnormalities. Jpn J Clin Oncol 49(5):458–464
25. Putman RK, Hunninghake GM, Deffebach PB et al (2017) Interstitial lung abnormalities are associated with acute respiratory distress syndrome. Am J Respir Crit Care Med 195(1):138–141
26. Raghav G, Remy-Jardin M, Myers JL et al (2018) Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 198(5):e644–e688
27. www.england.nhs.uk. Targeted screening for lung cancer with low radiation dose computed tomography. 2019
28. Lee TS, Jin KN, Lee HW et al (2020) Interstitial lung abnormalities and the clinical course in patients with COPD. Chest 159(1):237–243
disease insights from the genetic epidemiology of chronic obstructive pulmonary disease (COPDGene) study. Am J Respir Crit Care Med 199(3):286–301
53. Weatherley ND, Eaden JA, Stewart NJ et al (2019) Experimental and quantitative imaging techniques in interstitial lung disease. Thorax 74(6):611–619
54. Chen A, Karwoski RA, Gierada DS, Bartholmai BJ, Koo CW (2020) Quantitative CT analysis of diffuse lung disease. Radiographics 40(1):28–43
55. Guisado-Vasco P, Silva M, Duarte-Millan MA et al (2019) Quantitative assessment of interstitial lung disease in Sjogren's syndrome. PLoS One 14(11):e0224772
56. Hisa CC (2004) Signals and mechanisms of compensatory lung growth. J Appl Physiol (1985) 97(5):1992–1998
57. Kahn CE Jr (2017) From images to actions: opportunities for artificial intelligence in radiology. Radiology 285(3):719–720
58. Choy G, Khalizadeh O, Michalski M et al (2018) Current applications and future impact of machine learning in radiology. Radiology 288(2):318–328

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.